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(Received in final form May 14, 1980) The recent develo~aent of a high performance liquid chromatography assay method for the analysis of penicillamine in biological samples such as plasma, whole blood, and urine has provided a specific and sensitive assay method to aid in the study of penicillamine pharmacokinetics.
Several investigators have reported measuring the plasma conoentratlon of penicillemine.
Some of these investigators have indicated that the plasma must be assayed immediately.
However, such restrictions can limit the feasibility of a pharmacokinetlc study. The results of this paper demonstrate the instabillty of penlcillsmine in plasma, albumin solutions, and whole blood. The rate of loss of penicillemine was shown to be influenced by the concentration of albumin. As a result of the significant loss of penioillemine over a short p~riod of time, plasma or whole blood samples must be deproteina~immediately upon collection to avoid the loss of reduced penicill~ine.
Methods are presented for the preparation of biological sumpi~ so that the oxidation of penicillamine is prevented and the scruples can be held for several days prior to analysis.
Penicillamine has been used therapeutically since 1954 when it was first introduced by Walshe (I) for the treatment of Wilson's disease. Since that time a number of other uses for penicillamine have been advocated including the treatment of cystlnurla (2) , rheumatoid arthritis (3), metal intoxication (4), primary billiary cirrhosis (5) , chronic hepatitis (6) , and hyperbilirubinemia (7). Lyle recently has published an excellent review of penicillemine (8) .
reported primarily due to the lack of a specific and sensitive assay for penicillamine in biological fluids. Some investigators have reported pharmacokinetic studies of penicillamine using radiolabeled drug (9) (10) (11) (12) (13) (14) . However these studies are inappropriate as the radioactivity represents both metabolized and unchanged drug. Analytical methods for the analysis of penicillamine such as colorimetric (15, 16) , gas chromatographic (17), immunological (18, 19) and amino acid analyzer (20) have been developed. These methods have limitations such as non-speciflclty, low sensitivity, or require complex manipulations of the samples which renders their application in the analysis of pharmacokinetic samples inappropriate. The recent development of a high performance liquid chromatography (HPLC) method by Saetre and Rabenstein (21) for the analysis of penicillamine using an electrochemical detector has provided a simple, specific and sensitive analytical tool suitable for pharmacokinetic samples. We have used this HPLC method in our laboratory with some modifications to assess the stability of the reduced form of penicillamine in plasma, albumin solutions, and whole blood. The results of these studies and the corresponding implications for proposed pharmacokinetic studies are presented.
Methods
The stability of penicillamine in plasma, whole blood, and buffered albumin solutions was studied in vitro using plasma obtained from the American National Red Cross Blood Service (single donor source, citrate-phosphate anticoagulant used), whole blood obtained from a normal volunteer (ethylene diamine tetracetic acid disodium (EDTA) anticoagulant used) and normal human serum albumin 25% obtained from the American National Red Cross Blood Service.
The various concentrations of albumin solutions studied were prepared by diluting the normal human serum albumin 25% to the appropriate concentration using an isotonic pH:7.4 imidazole buffer (imidazole 4.3 g., HCI 0.1M. 225 ml., EDTA 250 mg., deionized water q.s. to 250 ml.).
All of the experiments were conducted at controlled temperatures. An alliquot of a biological fluid (25 ml.) was pipetted into a water jacketed flask. The flask was maintained at a constant temperature (10, 25, 37, or 55°C.) by circulating controlled temperature water through the water jacket from a Brinkmann MGW Lauda refrigerated water bath (model RC-3) equipped with a MGW Lauda (model T-2) temperature controller (Brinkmann Instruments, Inc. Westbury, N.Y. 11590). The temperature of the biological medium was allowed sufficient time to equilibrate to the controlled temperature before the addition of penicillamine. The biological medium was constantly stirred using a teflon coated magnetic stirring bar.
The experiments were started by the addition of a concentrated solution of D-penicillamine (Aldrich Chemical Co., Milwaukee, Wisconsin 53233) to the flask. At timed intervals following the addition, samples were withdrawn from the flask. For the initial rate studies, samples (1.O ml.) were obtained at .25, I, 2, 3, 4, 5, 7, 9, and 11 minutes after the penicillamlne addition. For the other studies, samples (2.0 ml.) were obtained at I, 10, 20, 30, 40, 50, 60, 707 80, and 90 minutes after addition of the concentrated penicillamine solution.
The samples were treated immediately to cause a precipitation of the proteins and a decrease in pH. The plasma samples were added to test tubes containing a trichloroacetlc acid solution (15% w/v) (0.25 ml. per ml. of sample). The albumin samples were added to test tubes containing a metaphosphoric acid solution (500 g./L.) (0.25 ml. per ml. of sample). The whole blood samples were added to test tubes containing an EDTA solution (200 mg./L.) (an equal volume to that of the sample) and the blood hemolyzed. Immediately an alliquot of a metaphosphorio acid solution (500 g./L.) (0.5 ml. per ml. of original sample) was added to the hemolyzed blood sample to precipitate the proteins. All of the precipitated samples were agitated to ensure complete precipitation and mixing. The initial rate samples were centrifuged at 15000 rpm (Eppendorf Micro Centrifuge model 5412, Brinkmann Instruments, Inc. Westbury, N.Y. 11590) for one minute. The supernatant fluids of these samples were decanted into clean test tubes and injected directly onto the HPLC. All of the other samples were centrifuged at 2500 rpm (Sorvall model RC-3 refrigerated centrifuge, Dupont Instruments, Newtown, Ct. 06470) for 6 minutes. The resulting protein free supernatant fluids were decanted and then filtered through a 0.45 ~. membrane filter (13 mm. Swlnnex with HATF01300 membrane filter, Millipore Corporation, Bedford, Mass, 01730) into clean test tubes. The concentration of penicillamine remained unchanged in the protein free supernatant of samples that were treated by the above methods. For penicillamine analysis 20 WI. alliquots of the samples were injected onto the HPLC system.
For the plasma and 5% albumin solutions studied at the three different temperatures (10, 25, and 37°C.) the theoretical initial concentration after the addition of the concentrated penicillsmine solution was 19.6 ~g./ml. The theoretical initial concentration was 38.3 ~g./ml. for the whole blood study and was 19.5 ~g./ml. in the 1, 3, 5, 7% albumin study. Initial rate studies were completed using initial concentrations of approximately 6, 23, and 200 ~g./ml. penicillamine for the 5% buffered albumin solutions only.
The HPLC method and electrochemical detector utilized for these studies are a modification of the HPLC method and detector reported previously by Saetre and Rabenstein (21) . Two stainless steel columns packed with Zipax SCX (Dupont Instruments, Wilmington, Del 19898) (0.41 x 5 cm. and 0.41 x 30 cm.) were used as the guard and analytical columns. A citrate/phosphate buffer (citric acid 0.03 M., and sodium dibasic phosphate 0.01M.) was used as the mobile phase. The flow rate was maintained at 2.6 ml./mln, and resulted in a back pressure of 300-400 psi. A mercury gold amalgam working electrode, Ag/AgCI reference electrode, and a glassy carbon auxiliary electrode were used in the electrochemical detector's transducer (model TL-6A Bioanalytical Systems, Inc. West Lafayette, Indiana 47906). The LC-4 amperometric controller (Bioanalytical Systems, Inc., West Lafayette, Indiana 47906) was used to maintain the potential of the working electrode at +0.01 V. vs. the Ag/AgCI reference electrode. Full details of the HPLC system will be published elsewhere.
The electrolysis method for the determination of total penicillamine content utilized the electrolysis cell described by Saetre and Rabenstein (21) . A Wenking potentiostat (model 61RS Brinkmann Instruments, Inc. Westbury, N.Y., 11590) with an external 270 ohm resister between the working and reference electrodes was used as a galvanostat to supply 6.4 mA of current to the electrolysis cell for the reduction of penicillamine disulfides to penicillamine. A citric acid solution (0.4 M.) was used to dilute the samples for the electrolysis procedure (equal volume used to that of the sample electrolyzed).
Results
The in vitro concentrations of penicillamine in plasma or albumin solutions have been shown to rapidly decrease with time. At the concentrations used, the rate of this loss was shown to be temperature dependent. Figure I shows the loss of penicillsmine at three temperatures that occurred when penicillsmine was added to normal human plasma in vitro. Figure 2 shows the loss of penicillamine in a 5% albumin solution at the same three temperatures. (All figures were computer drawn. The axis numerals do not represent the data accuracy).
The observed loss of penicillamine in these experiments is not due to the experimental conditions. The results of simultaneous control experiments using the same experiments/ conditions are shown in Table I . The control experiment results demonstrate that the loss of penicillamine is not due to a pH phenomenon alone. Aqueous solutions of penlcillemine are reported to be stable in the pH range from 2-4 and thus a loss of peniciilemine may be expected at physiological pH (pH=7.~). However, in the period of time considered in our experiments no penioillemine loss was observed at pH 7.~. 3) The imidazole buffer contained ~.3 g. imidazole, 250 mg. EDTA, 225 -I. HCI, q.s. to 250 ml. with deionized water. The temperature was controlled at 25°C.
The rate of loss was shown to be dependent on the concentration of albumin. Figure 3 shows the loss of penicillemlne that occurred when penicillemine was added to a I, 3, 5, or 7~ solution of albumin.
The loss of penicillemine may be due to more than one reaction. The results of the study of penicillamine in a 5~ albumin solution and in anticoagulated ~hole blood are shown in Figures 4 and 5 . Not all of the original amount of penicillemine could be regenerated using the electrolysis reductive procedure described in the methods. These results indicate that perhaps more than one product is being formed from the loss of penicillemine, a product that can he regenerated (ie. disulfides) end a product that cannot. (initial concentration of 23. ~g./ml.) squares=10°C., circles=25°C., triangles=37°C., stars=55°C. of penicillamine showed a temperature dependency of the rates and the Arrhenius plots for these data are shown in Figure 9 . However, the highest concentration of penicillamine (200 ug./ml.) represents a 10 fold excess in penicillamine and the data are not temperature dependent. A summary of the observed rate constants for these experiments is given in Table II . The activation energies for the 6 and 23 ug./ml, initial concentration experiments were 3.81 and 3.00 Kcal./mole respectively. 2) The approximate initial concentrations of penicil~amlne (6, 23, and 2~0 ~g./ml.) correspond to 4.02 x 10-M., 1.54 x 10 -7 M., and 1.34 x 10 -~ M.
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FIG. 9
Arrhenius Plots for Penicillamine Loss in a 5% Albumin Solution. circles= 6 ~g./ml. squares= 23 ~g./ml. initial concentrations.
The lack of a temperature dependency at the highest concentration studied indicates that the reaction meehaniem may be occurring at a "specific site" on the albumin molecule. Due to the 10 fold excess of penicillemine this "specific site" would always be occupied and thus the reaction would proceed at a constant rate independent of the temperature. Studies of albumin (22) have indicated that there is only one free sulfhydryl group in the whole molecule of albumin resulting from a eysteine residual. This or some other "specific site" may be responsible for the loss of penicillamine observed.
The loss of penicillamlne in biological samples such as plasma and whole blood presents a major obstacle for the successful completion of a phammacokinetic study of this drug. It is essential that the analytical method used to quantify the concentration of a drug measures the actual concentration of the sample as it was obtained from the subject or animal of study. The rapid disappearance of penieillamine in biological media demonstrated by the results of this paper eonfiPm the necessity of actiug quickly to stabilize the penicillamine present in a biological sample.
Previous investigators have also suggested the problem of penlcillamine loss. Russell et al. (23) stated that plasma samples must be assayed as soon as they are obtained. This approach, however, limits the feasibility of most pharmaeokinetic studies. Mann and Mitchell (24) stressed the necessity of using EDTA as an anticoagulant. However, the results shown in Figure 5 confiPm that penieillamine is lost even in blood where EDTA was used as the anticoagulant. I ) A concentrated solution of penieillamine was added to the whole blood supernatant or the control EDTA solutions to produce an approximate initial concentration of I. 97, 5.80 or 9.87 ~g./ml. Samples were refrigerated at 4°C. 2) A protein free hemolyzed whole blood supernatant was produced by the addition of 2.0 ml. of whole blood to 2.0 ml of EDTA solution (I g./ L.) followed by the addition of 1.0 ml. of metaphosphoric acid solution (500 g./L. ). After mixing and centrifuEaticn the supernatant ~as decanted and filtered through a membrane filter (0.45 P. ).
3) The EDTA solution (I E./L.) was used as a control for this experiment.
Previous investigators have shown the excellent stability of reduced penlcillamne in EDTA solutions (see reference 21) .
As demonstrated by the results presented in this paper, the protein content particularly the albumin of the samples plays a key role in the loss of penicillamine. If blood or plasma samples are treated immediately to precipitate the proteins and lower the pH the loss of penicillamine will be minimized. Tables III and IV show the results of a study of the stability of penicillamine in the protein free supernatant obtained from whole blood. The loss of penicillamlne was minimal in these studies over a period of 6-8 days. Recovery studies of penicillamine added to whole blood was 88.2, 93.7, 85.7, and 87.7 percent. 
100.
I) A concentrated penicillamine solution was added to the supernatant or control solution to produce an initial concentration of 5.00 ~g./ml and 15.0 ~g./ml. The samples were refrigerated at 4°C. 2) The protein free hemolyzed blood supernatant was produced by adding 2.0 ml. of whole blood to 7.0 ml. of EDTA (200 mE./L.) solution. After 1 minute 1.0 ml. of metaphosphoric acid (500 g./L.) solution was added. After 5 minutes the sample was centrifuged for 10 minutes at 2500 rpm. The supernatant was decanted and filtered through a membrane filter (0.45 W.). 3) An EDTA (1 g./L.) solution was used as a control.
Penicillamlne has excellent stability in EDTA solutions (see reference 21).
The studies reported here are for the in vitro initial rate of loss of penicillamlne. However, loss of penicillamine by similar reactions probably also occurs invivo.
Our results indicate that the rate of reaction is reduced with time. Thus the impact on pharmacokinetic samples collected minutes to hours after the dose of penicillamine probably will be less that the initial rate of loss demonstrated by our results. Nevertheless, it is important that all samples be deproteinated as soon an possible alter they are collected from the subject or animal being studied. The whole blood treatment procedure used in the above studies can generally be completed in less that two minutes.
In ~itro distribution studies of penicillamine in whole blood indicate that most of the penicillamlne is found in the extracellular plasma compartment.
Thus when the cell lysis occurs in the whole blood procedure, a "dilution" of the sample results beyond that caused by the addition of the EDTA diluent alone. In addition, the procedure for the treatment of whole blood samples results in a greater dilution of the actual analytical samples than is necessary to process an equivalent plasma sample (see methods). These factors coupled together mean that the analytical sample resulting from the whole blood procedure is less conoentrated than the analytical sample obtained from plasma of the same blood sample. Thus as the limit of sensitivity of the analytical assay is approached, plasma samples can be assayed for a longer period of time because of their relative higher concentration. Due to this advantage, plasma samples may be more appropriate for pharmacokinetic studies of penicillamine.
To prevent the excessive loss of penicillamine, however, the plasma must be separated from the whole blood and deproteinated as quickly as possible. For this purpose we employ a micro centrifuge (15000 rpm -30 sec.) to separate heparlnized whole blood samples into plasma and packed cells. The plasma is then treated as described in the methods above. A recovery study of penicillamine added to normal plasma yielded from 103 to 109 percent. Using this methodology the blood samples can generally be processed (plasma separated and proteins precipitated) in less than two minutes.
